Tyrosine ligation process
US-9149541-B2 · Oct 6, 2015 · US
Tyrosine-specific functionalized insulin and insulin analogs
US11530250B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11530250-B2 |
| Application number | US-201916980579-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 18, 2019 |
| Priority date | Mar 22, 2018 |
| Publication date | Dec 20, 2022 |
| Grant date | Dec 20, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to tyrosine-specific functionalized insulin analogs and processes of making such tyrosine-specific functionalized insulin analogs using R-3H-1,2,4-triazoline-3,5-(4H)diones (PTAD).
First claim
Opening claim text (preview).
What is claimed: 1. A compound, or pharmaceutically acceptable salt thereof, selected from:
Assignees
Inventors
Classifications
- C07K14/62Primary
Insulins · CPC title
by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids · CPC title
- A61K47/545Primary
Heterocyclic compounds (A61K47/558 takes precedence) · CPC title
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11530250B2 cover?
- The present invention relates to tyrosine-specific functionalized insulin analogs and processes of making such tyrosine-specific functionalized insulin analogs using R-3H-1,2,4-triazoline-3,5-(4H)diones (PTAD).
- Who is the assignee on this patent?
- Merck Sharp & Dohme, Kekec Ahmet, Kevin Nancy Jo, and 5 more
- What technology area does this patent fall under?
- Primary CPC classification C07K14/62. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).